5.75
+0.02(+0.35%)
Currency In USD
| Previous Close | 5.73 |
| Open | 5.74 |
| Day High | 5.75 |
| Day Low | 5.73 |
| 52-Week High | 12.96 |
| 52-Week Low | 3.73 |
| Volume | 48,807 |
| Average Volume | 54,556 |
| Market Cap | 34.66M |
| PE | -0.27 |
| EPS | -21.4 |
| Moving Average 50 Days | 5.6 |
| Moving Average 200 Days | 5.84 |
| Change | 0.02 |
If you invested $1000 in Science 37 Holdings, Inc. (SNCE) since IPO date, it would be worth $28.08 as of May 10, 2025 at a share price of $5.75. Whereas If you bought $1000 worth of Science 37 Holdings, Inc. (SNCE) shares 3 years ago, it would be worth $93.04 as of May 10, 2025 at a share price of $5.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site
Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
GlobeNewswire Inc.
Jan 14, 2025 1:00 PM GMT
Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical ResearchMORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces t
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
GlobeNewswire Inc.
Nov 21, 2024 1:00 PM GMT
MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical comp